BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

Core Insights - BridgeBio Pharma, Inc. announced the presentation of clinical outcomes and quality of life measures related to acoramidis for treating variant transthyretin amyloid cardiomyopathy (ATTR-CM) at the Heart Failure 2025 Congress in Belgrade, Serbia from May 17-20, 2025 [1][2] Group 1: Clinical Presentations - A rapid-fire abstract will present results showing that acoramidis improves serum TTR levels in patients with wild-type or variant ATTR-CM [3] - Two moderated ePosters will discuss the effect of acoramidis on functional capacity and quality of life, as well as its impact on all-cause mortality, cardiovascular hospitalization, and NT-proBNP levels in patients with variant ATTR-CM [3] - A post-hoc analysis will be presented indicating that acoramidis treatment is associated with a lower incidence of atrial fibrillation-related events in patients with ATTR-CM [3] Group 2: Real-World Data - Three moderated ePosters will cover disease progression of ATTR-CM in a real-world setting, a retrospective cohort study on the time from manifestation to diagnosis, and data on the causes of death in ATTR-CM patients [2][4] Group 3: Product Information - Attruby (acoramidis) is indicated for treating the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and related hospitalizations [5] - Adverse reactions reported include diarrhea (11.6% vs 7.6% in placebo) and upper abdominal pain (5.5% vs 1.4% in placebo), with most being mild and resolving without drug discontinuation [6][7] Group 4: Company Overview - BridgeBio Pharma is focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases, with a pipeline ranging from early science to advanced clinical trials [8]